Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

given to CVD patients in combination with statins. ApoA-I therapy has the potential to reduce the overall cost of cardiovascular disease, which is estimated in the U.S. at US $475 billion annually, by 5% to 16%.

Resverlogix is also pleased to announce that it will host a live teleconference today, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of this clinical trial. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast is posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix090928.html. The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... growth in the in vitro diagnostic (IVD) test industry, ... Kalorama Information. The healthcare market researcher listed more than 25 ... that could be the future of IVD products. Kalorama details ... industry, The Worldwide Market for In Vitro Diagnostic ...
(Date:10/22/2014)... and BOSTON , Oct. 22, ... a leading global specialty pharmaceutical company, and Rhythm, a ... an exclusive option to acquire Rhythm,s wholly owned subsidiary, ... peptide ghrelin agonist, for the treatment of diabetic gastroparesis ... has completed a successful Phase 2 trial of relamorelin ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... SHANGHAI, June 16 /PRNewswire-Asia/ -- ... announced,today that its animal facility in Shanghai has passed ... Sundia management and staff are praised,for providing good facilities ... , The inspection and audit ...
... June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis,(ASX: PXS; Nasdaq: ... of its,recently completed international Phase III trial of Bronchitol in ... Cystic Fibrosis,Conference in Brest, France. , ... June by Dr Diana,Bilton of the Royal Brompton Hospital, London. ...
... , DETROIT, June 15 Business, nonprofit and ... the manufacturing sector that includes enacting pro-industry policies and ... investment, and creating new demand through innovation and globalization. ... at The National Summit in Detroit agreed that economic ...
Cached Biology Technology:Sundia's Animal Facility Passed Client and Government Inspection 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 2Top CEOs Declare America's Manufacturing Sector Requires Pro-Industry Policies, Capital Management and Innovation to Maintain Economic Leadership 3
(Date:10/16/2014)... a new synthesis of recent research findings to inform ... the two states. , The Ecology and Management ... A Synthesis of the Relevant Biophysical Science and Implications ... by the U.S. Forest Service,s Pacific Northwest Research Station, ... for a synthesis of the large body of scientific ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... One in eight women in the United States will receive ... is the second leading cause of cancer-related death in women. ... possible treatment for each patient. "Our research shows that ... without getting any treatment at all, other than a lumpectomy," ...
... mobile phone charger at home when you go for ... norm one day as scientists from Nanyang Technological University ... a microchip that uses 30 times less electricity while ... The technology, dubbed PCMOS (probabilistic complementary metal-oxide semiconductor) was ...
... of genetic factors associated with heart attacks has identified ... that appear to increase the risk for early-onset myocardial ... Consortium, based on information from a total of 26,000 ... Genetics and is receiving early online release. ...
Cached Biology News:New test for breast cancer will help guide treatment choices 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 2Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy 3International study identifies gene variants associated with early heart attack 2International study identifies gene variants associated with early heart attack 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... the Beacon 2000 instrument can be used ... Beacon 2000 Data Manager Software provides the ... directly from the instrument. These data can ... available spreadsheets, such as Microsoft Excel or ...
... This kit allows for quick and reproducible immunoprecipitation ... The system is more reproducible than regular IPs, ... protein A/G agarose without disrupting the agarose bed. ... and Release is reversible, and elution of the ...
... self locking design in ice/water bath ... product number, created to easily match ... availability yet, please order under the ... customer service for assistance. ID clarifier: ...
Biology Products: